August 16, 2018. Protecting the public health requires that EPA’s draft guidance for applying a systematic review process for risk evaluations is scientifically valid, reliable, and accepted by the scientific community. It should consider the totality of the scientific evidence without often irrelevant or industry-centric requirements that would reduce the impact of high quality sources or exclude them.
Read More »On Health Policy
Comments on FDA’s Limited Population Pathway for Antibacterial and Antifungal Drugs
August 13, 2018. Everyone agrees that there is a need to develop new antimicrobials to treat serious or life-threatening infections. The only way to make sure that new drugs are safe and effective is by requiring well-designed and valid clinical trials.
Read More »Letter to Members of Congress Opposing the “Accurate Labels Act”
July 11, 2018. We urge you to oppose this dangerous family-unfriendly legislation that: undermines the health of the American public; eliminates states’ existing ability to inform their citizens about the ingredients of products and the dangers that they may pose; and keeps Americans in the dark about the products they bring into their homes.
Read More »Letter from Nonprofits to DC Mayor and Other Officials About Dangers of Artificial Turf and Playgrounds
July 10, 2018. DC Nonprofits write to DC Officials about the dangers of artificial turf and playgrounds. Both environmental and health concerns are discussed, and officials are advised to stop the usage of this kind of turf around children.
Read More »NCHR Testimony at FDA on the Benefits and Risks of Systemic Fluoroquinolone Antibacterial Drugs
November 5, 2016. While quinolones can be life-saving drugs for certain types of infections, we must re-examine their safety and efficacy in light of new information to ensure the benefits outweigh the harms.
Read More »